


Express Mail Label No.: 41044088US
Date of Deposit: March 15, 2000

Attorney Docket No. 19705-001 (AMC-1)



#5
w/cont
1997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Grasso *et al.*
ASSIGNEE: Albany Medical College
SERIAL NUMBER: 09/377,081 EXAMINER: Not Yet Assigned
FILING DATE: August 19, 1999 ART UNIT: 1646
FOR: LEPTIN-RELATED PEPTIDES

Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

Foreign Patent Documents:

B1	WO	97/46585	Al-Barazani	12/11/97
B2	WO	96/34885	Smith	11/07/96
B3	GB	2 292 382 A	Friedman <i>et al.</i>	02/21/96
B4	WO	98/12224	Ertl <i>et al.</i>	03/26/98
B5	WO	98/24896	Devos <i>et al.</i>	06/11/98
B6	WO	98/18486	Rao <i>et al.</i>	05/07/98
B7	WO	98/17626	Dix	04/30/98
B8	WO	97/48419	Morsy <i>et al.</i>	12/24/97

Other Prior Art – Non Patent Literature Documents:

C1	Grasso <i>et al.</i> , Endocrinology 138(4):1413-1418 (1997).
C2	Martinez <i>et al.</i> , Journal of Physiology and Biochemistry 52(2): 123-124 (1996).
C3	Fruhbeck <i>et al.</i> , Regulatroy Peptides 73(2) 83-87 (1998)
C4	Sampson <i>et al.</i> , Endocrinology 137(11): 5182-5185 (1996).
C5	Grasso <i>et al.</i> , Regulatory Peptides 85(23): 93-100 (1999).

This Information Disclosure Statement is being been filed:

☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97

APPLICANTS:
U.S.S.N.:


Grasso et al.
09/377,081

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 19705-001.

Respectfully submitted,



Attorney name(s) and Reg. No.

Attorney(s) for Applicants

c/o MINTZ, LEVIN

One Financial Center
Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: March 15, 2000

TRADOCS:1306899.1(S0#R01!.DOC)